1
EXHIBIT 11.1
INCYTE PHARMACEUTICALS, INC.
STATEMENT RE COMPUTATION OF EARNINGS (LOSS) PER SHARE
(In thousands, except per share amounts)
Three Months Ended Six Months Ended
June 30, June 30,
------------------- -------------------
1997 1996 1997 1996
------- ------- ------- -------
Primary Earnings (Loss) Per Share
- ---------------------------------
Weighted average common shares outstanding
during the period 10,518 10,104 10,486 10,069
Adjustment for dilutive effect of outstanding
stock options 916 -- 957 --
------- ------- ------ ------
Weighted average common and common
equivalent shares used for primary earnings
(loss) per share 11,434 10,104 11,443 10,069
======= ======= ======= =======
Net income (loss) 1,942 (1,596) 2,923 (3,634)
======= ======= ======= =======
Net income (loss) per share $ 0.17 ($ 0.16) $ 0.26 ($ 0.36)
======= ======= ======= =======
Fully Diluted Earnings (Loss) Per Share
- ---------------------------------------
Weighted average common shares outstanding
during the period 10,518 10,104 10,486 10,069
Adjustment for dilutive effect of outstanding
stock options 1,013 -- 1,006 --
------- ------- ------- -------
Weighted average common and common
equivalent shares used for fully diluted earnings
(loss) per share 11,531 10,104 11,492 10,069
======= ======= ======= =======
Net income (loss) 1,942 (1,596) 2,923 (3,634)
======= ======= ======= =======
Net income (loss) per share $ 0.17 ($ 0.16) $ 0.25 ($ 0.36)
======= ======= ======= =======
Page 16 of 17